Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2261 | MVA-BN-Filo Wiki | 1.00 |
| drug1199 | Dexmedetomidine Injectable Product Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D000071257 | Emergence Delirium NIH | 1.00 |
| D003693 | Delirium NIH | 0.45 |
| D007249 | Inflammation NIH | 0.17 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is: a) to assess adverse maternal/fetal outcomes in pregnant women randomized to receive the 2- dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo [Group A]) and in control women (unvaccinated pregnant women [Group B]); and b) to assess adverse neonatal/infant outcomes in neonates/infants born to women randomized to receive the 2-dose Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo [Group A]) and in neonates/infants born to control women (unvaccinated during pregnancy [Group B]).
Description: Percentage of participants with maternal deaths will be reported. Maternal death is the death of a woman while pregnant or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management but not from accidental or incidental causes.
Measure: Percentage of Participants with Maternal Deaths Time: Up to 6 weeks post-completion/termination of pregnancy (Up to 43 weeks)Description: Percentage of participants with spontaneous abortion will be reported. Spontaneous abortion is a pregnancy loss that occurs up to 21 weeks 6 days of gestation.
Measure: Percentage of Participants with Spontaneous Abortion Time: Up to 6 weeks post-completion/termination of pregnancy (Up to 43 weeks)Description: Percentage of participants with stillbirth will be reported. Stillbirth is fetal death at or after 21 weeks 6 days of gestation.
Measure: Percentage of Participants with Stillbirth Time: Up to 6 weeks post-completion/termination of pregnancy (Up to 43 weeks)Description: Percentage of participants on the pathways to preterm birth will be reported. Pathways to preterm birth is a clinical syndrome characterized by any one or some combination of the following four pathways: 1) Premature preterm rupture of membranes, 2) Preterm labor, 3) Insufficient cervix, 4) Provider- initiated preterm birth.
Measure: Percentage of Participants on the Pathways to Preterm Birth Time: Up to 6 weeks post-completion/termination of pregnancy (Up to 43 weeks)Description: Percentage of participants with pre-eclampsia/ eclampsia will be reported. Pre-eclampsia is new-onset or worsening of existing hypertension with new-onset proteinuria after 20 weeks gestation.
Measure: Percentage of Participants with Pre-eclampsia/ eclampsia Time: Up to 6 weeks post-completion/termination of pregnancy (Up to 43 weeks)Description: Percentage of participants with antenatal bleeding will be reported. Antenatal bleeding is vaginal or suspected intrauterine, intraperitoneal, or retroperitoneal bleeding in the second or third trimester of pregnancy.
Measure: Percentage of Participants with Antenatal Bleeding Time: Up to 6 weeks post-completion/termination of pregnancy (Up to 43 weeks)Description: Percentage of participants with postpartum hemorrhage will be reported. Postpartum hemorrhage is genital bleeding after delivery estimated at 1000 ml or more, or leading to hypotension or blood transfusion, or leading to severe maternal outcome (maternal death or maternal near miss) as defined by World Health Organization (WHO).
Measure: Percentage of Participants with Postpartum Hemorrhage Time: Up to 6 weeks post-completion/termination of pregnancy (Up to 43 weeks)Description: Percentage of newborns with congenital anomalies born to participants will be reported. Congenital Anomalies are abnormalities of body structure or function that are present at birth and are of prenatal origin. Major congenital malformations include structural changes that have significant medical, social or cosmetic consequences for the affected individual, and typically require medical intervention (for example, cleft lip and spina bifida).
Measure: Percentage of Newborns with Congenital Anomalies born to Participants Time: From birth up to 14 weeks of ageDescription: Percentage of newborns small for gestational age (SGA) born to participants will be reported. Small for gestational age (SGA) means newborns that are smaller in size than normal for the gestational age (weight below the tenth percentile for the gestational age using Rwandan standards).
Measure: Percentage of Newborns Small for Gestational age (SGA) born to Participants Time: From birth up to 14 weeks of ageDescription: Percentage of newborns with low birth weight born to participants will be reported. Low birth weight newborns are babies, weighing less than 2500 grams at birth (regardless of child's sex).
Measure: Percentage of Newborns with Low Birth Weight born to Participants Time: From birth up to 14 weeks of ageDescription: Percentage of newborns with preterm birth born to participants will be reported. Preterm birth means neonates born at less than 37 weeks' gestation.
Measure: Percentage of Newborns with Preterm Birth born to Participants Time: From birth up to 14 weeks of ageDescription: Percentage of neonatal deaths in neonates born to participants will be reported. Neonatal deaths mean neonate dying in the first 28 days of life.
Measure: Percentage of Neonatal Deaths in Neonates Born to Participants Time: From birth up to 14 weeks of ageDescription: Percentage of infants (of participants) who fail to thrive will be reported. Failure to thrive means weight for age deceleration through at least 2 centile spaces on growth chart of infants or as defined according to Rwandan standards.
Measure: Percentage of Infants (of Participants) who Fail to Thrive Time: From birth up to 14 weeks of ageDescription: A SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
Measure: Percentage of Participants (Pregnant Women) with Serious Adverse Events (SAEs) Time: Up to 23 monthsDescription: A SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
Measure: Percentage of Newborns (Born to Participants) with SAEs Time: From birth up to 23 monthsDescription: Solicited local AEs: pain/tenderness, erythema, and induration/swelling. Solicited systemic AEs: headache, fatigue, myalgia, arthralgia, chills and fever.
Measure: Percentage of Participants with Solicited Local and Systemic Adverse Events (AEs) Time: 7 Days after each vaccination (up to Day 64)Description: Unsolicited AEs will include all AEs for which the participant is not specifically questioned in the participant diary.
Measure: Percentage of Participants with Unsolicited AEs Time: 28 Days after each vaccination (up to Day 85)Description: Percentage of participants with normal delivery will be reported.
Measure: Percentage of Participants with Normal Delivery Time: Up to 43 WeeksDescription: Percentage of participants with caesarian section will be reported.
Measure: Percentage of Participants with Caesarian Section Time: Up to 43 WeeksDescription: Blood samples will be collected for analysis of binding antibodies against EBOV GP using Filovirus Animal Non-Clinical Group (FANG) enzyme-linked immunosorbent assay (ELISA).
Measure: Percentage of Participants with Anti-Ebola virus (EBOV) Glycoprotein (GP) Binding Antibodies Time: Day 1 (pre-dose 1), Day 78 (21 days post-dose 2), at delivery (Group A subset only), and 1 year post-dose 1 (Day 365)Description: Blood samples will be collected from infants at 14 weeks of age for analysis of binding antibodies against EBOV GP using Filovirus Animal Non-Clinical Group (FANG) enzyme-linked immunosorbent assay (ELISA).
Measure: Percentage of Infants (Born to Participants) with Anti-Ebola virus (EBOV) Glycoprotein (GP) Binding Antibodies Time: From birth up to 14 weeks of ageAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports